The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells
Authors:
Open Access
- 5 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (67) , 111931-111942
Abstract
The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cellsKeywords
This publication has 40 references indexed in Scilit:
- Medical management of side effects related to CAR T cell therapy in hematologic malignanciesExpert Review of Hematology, 2016
- IL-7 signaling imparts polyfunctionality and stemness potential to CD4+ T cellsOncoImmunology, 2016
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015
- CAR therapy: the CD19 paradigmJournal of Clinical Investigation, 2015
- Effects of cyclophosphamide on immune system and gut microbiota in miceMicrobiological Research, 2015
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?Nature Clinical Practice Oncology, 2006
- Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemiaAnnals of Hematology, 1999